SPRO — Spero Therapeutics Share News
0.000.00%
Last trade - 00:00- $64.64m
- $13.87m
- $66.80m
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)
Brief: GSK Says cUTI Oral Antibiotic Tebipenem Approved By US FDA
US FDA approves GSK's oral antibiotic for drug-resistant UTIs
Brief: FDA Approves First Oral Carbapenem Therapy For Complicated Urinary Tract Infections
Spero Therapeutics Q1 revenue drops on decreased clinical activity
Brief: Spero Therapeutics Q1 Operating Expenses USD 7.796 Million
Spero Therapeutics Q4 revenue nearly triples, swings to profit
Brief: Spero Announces NDA Resubmission Of Tebipenem Hbr By Gsk To The FDA
Spero Therapeutics Q3 net loss narrows
Brief: Spero Therapeutics Q3 EPS USD -0.13
Brief: GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBr
Spero Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Spero Therapeutics Q2 EPS USD -0.03
Spero Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Spero Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Nvidia, Salesforce, Kestrel Group